{"id":"relvar-breo","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness"}]},"_chembl":{"chemblId":"CHEMBL1676","moleculeType":"Small molecule","molecularWeight":"538.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone furoate binds to glucocorticoid receptors in the airways, suppressing inflammatory responses and reducing mucus production. Vilanterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improving airflow. Together, these agents provide both anti-inflammatory and bronchodilatory effects in a single maintenance inhaler.","oneSentence":"RELVAR/BREO is a combination inhaler containing fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:01.337Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment (in some markets)"}]},"trialDetails":[{"nctId":"NCT05757102","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-04-25","conditions":"Asthma","enrollment":292},{"nctId":"NCT03380429","phase":"PHASE4","title":"A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-01-31","conditions":"Asthma","enrollment":437}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"RELVAR/BREO","genericName":"RELVAR/BREO","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RELVAR/BREO is a combination inhaler containing fluticasone furoate (an inhaled corticosteroid) and vilanterol (a long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment (in some markets).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}